Nonalcoholic Steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver (steatosis), along with inflammation and hepatocellular injury (ballooning), which can lead to fibrosis, cirrhosis, and even liver cancer (hepatocellular carcinoma).
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Nonalcoholic Steatohepatitis Prevalence Cases
</li>
<li dir="ltr" aria-level="1">
Total Nonalcoholic Steatohepatitis Diagnosed Prevalence Cases
</li>
<li dir="ltr" aria-level="1">
Nonalcoholic Steatohepatitis Gender-specific Diagnosed Prevalence Cases
</li>
<li dir="ltr" aria-level="1">
Nonalcoholic Steatohepatitis Severity-specific Diagnosed Prevalence Cases
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-epidemiology-forecast">Nonalcoholic Steatohepatitis Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2023, there were an estimated 42 million NASH cases in the 7MM, with around 15 million diagnosed. This number is expected to rise by 2034.
</li>
<li dir="ltr" aria-level="1">
The U.S. had the highest diagnosed cases (9.4 million), followed by the EU4 and UK (3.6 million) and Japan (~2.5 million).
</li>
<li dir="ltr" aria-level="1">
Males accounted for 56% of diagnosed NASH cases across the 7MM.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market">Nonalcoholic Steatohepatitis Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The NASH market size in the 7MM was approximately USD 2.1 billion in 2023 and is expected to grow through 2034.
</li>
<li dir="ltr" aria-level="1">
The U.S. held the largest share, with a market size of around USD 1.52 billion in 2023, projected to increase further.
</li>
<li dir="ltr" aria-level="1">
In Japan, the NASH market was valued at nearly USD 260 million in 2023, with growth anticipated by 2034.
</li>
</ul>
<h3 dir="ltr">Nonalcoholic Steatohepatitis Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The increasing incidence of obesity, type 2 diabetes, and metabolic syndrome is directly fueling the growth of NASH cases worldwide.
</li>
<li dir="ltr" aria-level="1">
A robust pipeline, including FXR agonists, GLP-1 receptor agonists, and PPAR agonists, is expected to bring the first wave of disease-modifying treatments, boosting market potential.
</li>
<li dir="ltr" aria-level="1">
Improved screening methods, greater physician awareness, and better non-invasive diagnostic tools are leading to earlier and more frequent NASH diagnoses.
</li>
</ul>
<h3 dir="ltr">Nonalcoholic Steatohepatitis Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
As of now, there are no FDA- or EMA-approved drugs specifically for NASH, which limits treatment options and delays widespread clinical adoption.
</li>
<li dir="ltr" aria-level="1">
NASH involves multiple pathways (inflammation, lipid metabolism, fibrosis), making drug development challenging and increasing the risk of late-stage trial failures.
</li>
<li dir="ltr" aria-level="1">
Stringent regulatory requirements and the need for long-term outcome data make clinical trials expensive and time-consuming, deterring smaller players.&nbsp;
</li>
</ul>
<h3 dir="ltr">Nonalcoholic Steatohepatitis Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Inventiva Pharma
</li>
<li dir="ltr" aria-level="1">
Zydus Therapeutics
</li>
<li dir="ltr" aria-level="1">
Novo Nordisk A/S
</li>
<li dir="ltr" aria-level="1">
Eli Lilly and Company
</li>
<li dir="ltr" aria-level="1">
Madrigal Pharmaceuticals, Inc
</li>
<li dir="ltr" aria-level="1">
Terns, Inc.
</li>
<li dir="ltr" aria-level="1">
Intercept Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Enyo Pharma
</li>
<li dir="ltr" aria-level="1">
89bio, Inc.
</li>
<li dir="ltr" aria-level="1">
Akero Therapeutics
</li>
</ul>
And others

Nonalcoholic Steatohepatitis (NASH) Market Infographic

Nonalcoholic Steatohepatitis (NASH) Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.